MS treatment gets personal: could tailored infusions be just as effective?
NCT ID NCT05296161
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study compares the standard fixed-interval dosing of ocrelizumab (every 24 weeks) with a personalized approach where infusions are given only when B cell levels rise above a certain threshold. The goal is to see if the personalized schedule is just as good at preventing relapses and new brain lesions, while potentially reducing side effects and costs. The trial involves 296 adults with relapsing-remitting MS who have already been on ocrelizumab for at least a year.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ocrelizumab (Ocrevus)
What this could lead to
If successful, this could lead to a more personalized, safer, and cheaper way to manage relapsing-remitting MS by tailoring infusion intervals to each patient's immune response.
What could go wrong
This is a Phase 4 trial, so the drug is already approved. The main question is whether personalized dosing is as effective as standard dosing; there is a small risk of increased disease activity if intervals are extended too far.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSING - REMITTING MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Amsterdam UMC, location VU
Amsterdam, North Holland, 1081 HV, Netherlands